Mirum Pharmaceuticals MIRM
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 80th percentile, 5-year average -27.0x
Near the bottom of its 5-year range · 5th percentile, 5-year average -20.2x
Around its usual level · 43rd percentile, 5-year average 13.1x
#4441 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -113.24 | – | -20.18 | 5% (cheaper than usual) | – |
| PE | -6.50 | -40.76 | -26.98 | 80% (pricier than usual) | – |
| PS | 9.15 | 7.45 | 13.12 | 43% (cheaper than usual) | #4441 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on MIRM.
Sign in to join the discussion.